What question did this study set out to answer?

To assess the impact of biosimilar competition on patient out-of-pocket costs for rheumatology biologics.

Patient out-of-pocket costs and rheumatology biosimilar competition

View Full Paper

Ask AI

Bookmark

To assess the impact of biosimilar competition on patient out-of-pocket costs for rheumatology biologics.
Analyzed claims from the Merative MarketScan Commercial Database from January 1, 2011, to December 31, 2023.
Conducted a Callaway and Sant'Anna difference-in-differences analysis focusing on biologics with and without biosimilars.
Included patients with at least 2 drug claims for infliximab, rituximab, and adalimumab, comparing them with a control group.
Average annual out-of-pocket savings of -$1,133.90 (95% CI -$1,200.35 to -$1,067.45) for infliximab patients.
Average savings of -$1,437.63 (95% CI -$1,549.98 to -$1,325.28) for rituximab patients.
No significant savings observed for adalimumab in a scenario analysis excluding the year before biosimilar entry.

No takes yet. Share an insight, caveat, or question.

Randomized trial assesses biosimilar competition's effect on out-of-pocket costs for rheumatology biologics, indicating significant patient savings.

Dayer et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial assesses biosimilar competition's effect on out-of-pocket costs for rheumatology biologics, indicating significant patient savings.